 Deciphera Pharmaceuticals, Inc. NASDAQ:DCPH today announced that the Australian Therapeutic Goods Administration TGA has approved QINLOCKTM ripretinib, a switch-control tyrosine kinase inhibitor, for the treatment of adult patients with advanced gastrointestinal stromal tumor GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib. The QINLOCK Marketing Authorisation Application was approved by the TGA under Project Orbis, an initiative of the U.S. Food and Drug Administrations FDA Oncology Center of Excellence designed to provide a framework for concurrent submission and review of oncology products among international partners. QINLOCK is also approved by the U.S. FDA for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib, and authorized by Health Canada for the treatment of adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib. 